GC Genome

At a glance

GC Genome filed 15 disclosures in the last 12 months, including 2 insider and 2 5% holder. The most recent key filing was on Feb 3: A major holder's stake fell from 7.85% to 4.04% (open-market sale).

Revenue for 2025 was ₩31.5B, up 21.8% on 2024. Operating margin was 3.9% against -4.8% a year earlier. Debt was 8% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩15.7B and operating profit of ₩572.6M.

The 2025 annual report lists 131 employees with an average tenure of 3.8 years and average pay of ₩53.2M, #1547 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩167.8M each on average. It paid no cash dividend for 2025. (주)녹십자 and related parties held 42.56% at year end.

Of 2 recent 5%+ holder reports, 0 raised and 2 cut a stake; the largest stake reported was 7.85% on Dec 15.

From the 2025 annual report

Staff: 131 (48 men, 83 women), of whom 9 on fixed-term contracts. Total pay for the year: ₩6.7B. Directors and auditors: 6, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)녹십자 holds 19.60%; with 16 related parties the group holds 42.56% of common shares at year end (from 51.47% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports